2 626

Cited 144 times in

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib

DC Field Value Language
dc.contributor.author신상준-
dc.contributor.author임종근-
dc.contributor.author장준-
dc.contributor.author조병철-
dc.contributor.author최혜진-
dc.contributor.author김세규-
dc.contributor.author김유진-
dc.contributor.author김주항-
dc.contributor.author김호근-
dc.contributor.author박무석-
dc.contributor.author박종필-
dc.contributor.author손주혁-
dc.date.accessioned2014-12-21T16:44:37Z-
dc.date.available2014-12-21T16:44:37Z-
dc.date.issued2007-
dc.identifier.issn0732-183X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/96269-
dc.description.abstractPURPOSE: This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib. PATIENTS AND METHODS: The study included stage IIIB/IV recurrent or metastatic NSCLC patients who received two or three prior chemotherapy regimens and showed progressive disease within 4 months of gefitinib therapy discontinuation. Patients received erlotinib 150 mg/d until disease progression or unacceptable toxicity. Epidermal growth factor receptor (EGFR) mutations and other genetic abnormalities were analyzed from available tumor samples. RESULTS: Patient and disease characteristics (N = 21) included median age 56 years; number of prior chemotherapy regimens (three; n = 11); female sex (n = 11); adenocarcinoma (n = 15); and never-smoker status (n = 11). Among the 17 patients with tumor samples available, EGFR mutations were detected in five. The disease control rate (DCR) and response rate (RR) for all patients were 28.6% and 9.5%, respectively. The median duration of disease control was 125 days. The median time to progression and overall survival were 60 days and 158 days, respectively. Patients who had stable disease (SD) while receiving gefitinib showed significantly higher DCR (75% v 17.6% in non-SD patients; P = .050) and RR (50.0% v 0% in non-SD patients; P = .029). Among 17 patients with biomarker results available, those lacking EGFR mutations who had SD while receiving gefitinib showed significantly higher DCR and RR. CONCLUSION: Erlotinib seems to be a potential therapeutic option for the treatment of advanced NSCLC patients with wild-type EGFR who had SD while receiving gefitinib.-
dc.description.statementOfResponsibilityopen-
dc.format.extent2528~2533-
dc.relation.isPartOfJOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHBiomarkers, Tumor/analysis-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHDisease Progression-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHErlotinib Hydrochloride-
dc.subject.MESHFemale-
dc.subject.MESHGefitinib-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProtein Kinase Inhibitors/therapeutic use*-
dc.subject.MESHQuinazolines/therapeutic use*-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.titlePhase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorChong-Kun Im-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorHoguen Kim-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorSang-Joon Shin-
dc.contributor.googleauthorYu Jin Kim-
dc.contributor.googleauthorHye Jin Choi-
dc.contributor.googleauthorJong Pil Park-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorMoo-Suk Park-
dc.identifier.doi10.1200/JCO.2006.10.4166-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02105-
dc.contributor.localIdA03402-
dc.contributor.localIdA03472-
dc.contributor.localIdA03822-
dc.contributor.localIdA04219-
dc.contributor.localIdA00602-
dc.contributor.localIdA00945-
dc.contributor.localIdA01183-
dc.contributor.localIdA01457-
dc.contributor.localIdA01665-
dc.contributor.localIdA01995-
dc.contributor.localIdA00787-
dc.relation.journalcodeJ01331-
dc.identifier.eissn1527-7755-
dc.identifier.pmid17577030-
dc.identifier.urlhttp://jco.ascopubs.org/content/25/18/2528.long-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameIm, Chong Kun-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Yoo Jin-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Ho Keun-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNamePark, Jong Pil-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorIm, Chong Kun-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Ho Keun-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorPark, Jong Pil-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorKim, Yoo Jin-
dc.rights.accessRightsnot free-
dc.citation.volume25-
dc.citation.number18-
dc.citation.startPage2528-
dc.citation.endPage2533-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL ONCOLOGY, Vol.25(18) : 2528-2533, 2007-
dc.identifier.rimsid35024-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.